NDTV Profit on MSN
Nifty at 30,000 by end of 2026? JPMorgan sees double-digit earnings growth, upgrades pharma ahead of Q1
JPMorgan sees Nifty 50 at 30,000 in its bull case, upgrades pharma to Neutral and expects double-digit India earnings growth ...
For FY27, experts are split in opinion; however, majority believe that TCS revenue growth will be impacted by macro headwinds ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results